Biosimilars 2020 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. Note that FDA still has not designated any biosimilar as interchangeable to its reference product. first submission July 2017; resubmitted Dec. first submission May 2017; resubmitted Oct. 2017; resubmitted Dec.
Let's personalize your content